Novo Nordisk: pharma accelerator with Evotec

(CercleFinance.com) - Last night, Novo Nordisk announced the launch of an "accelerator" with Germany's Evotec, aimed at developing new treatments for cardiometabolic diseases such as obesity and diabetes.


The project - dubbed "LAB eN2" - will combine the Danish pharmaceutical group's therapeutic, clinical and commercial capabilities with Evotec's expertise in molecule discovery and preclinical programs.

Four academic institutes - Harvard University, Mass General Brigham Health System, Yale and Beth Israel Deaconess Medical Center - have also agreed to join the project.

Several research concepts are set to be selected for further work by the researchers associated with "LAB eN2".

This announcement comes at a time when cardiometabolic diseases are increasing, with 537 million adults now affected by diabetes, while cardiovascular disease remains the leading cause of death worldwide.

It will also focus on rare blood diseases and endocrine disorders.


Copyright (c) 2023 CercleFinance.com. All rights reserved.